At a glance
- Originator University of Wisconsin-Madison
- Developer Canopus BioPharma
- Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules; Sulfhydryl compounds
- Mechanism of Action DNA repair enzyme stimulants; Glutathione transferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Mucositis
Most Recent Events
- 23 Jun 2008 Canopus receives approval from the South African Medicines Control Council to begin a phase II trial with CB 1400 as a mucositis protective agent in patients with cancer
- 19 Jun 2008 Preclinical trials in Cancer in USA (PO)
- 19 Jun 2008 Preclinical pharmacodynamics data released by Canopus BioPharma